Abstract
A clinical study evaluating a single-dose, oral granule formulation of secnidazole 2 g for the treatment of bacterial vaginosis (BV) was conducted and the results have been reported. Since then, the US Food and Drug Administration (FDA) has issued updated guidelines for clinical studies evaluating treatments for BV. The purpose of this post hoc analysis was to determine the effects of the updated FDA criteria issued in 2016 on enrollment and clinical response rates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
